EU regulators recommend against renewing approval for GSK's Blenrep
https://seekingalpha.com/news/4046976-eu-regulators-recommend-against-renewing-approval-for-gsks-blenrep?source=feed_sector_healthcare
Dec 15, 2023 - EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (GSK) blood cancer drug Blenrep. According to Reuters, a European Me
0
GSK looking to boost pipeline with respiratory, auto-immune deals - report
https://seekingalpha.com/news/4050326-gsk-looking-to-boost-pipeline-with-respiratory-auto-immune-deals-report?source=feed_sector_healthcare
Dec 26, 2023 - GSK plans to strengthen its drug portfolio through acquisitions in respiratory and auto-immune areas, with a focus on deals worth around $2 billion over the...
0
GSK, Pfizer-backed ViiV gets FDA okay for HIV drug for adolescents
https://seekingalpha.com/news/4087977-gsk-pfizer-backed-viiv-gets-fda-okay-for-hiv-drug-for-adolescents?source=feed_sector_healthcare
Apr 08, 2024 - ViiV Healthcare said it has received FDA approval for its drug Dovato in the treatment of HIV-1 infection in adolescents 12 years old and older. Read more here.
0
GSK shingles vaccine shown 82% effective 11 years after vaccination
https://seekingalpha.com/news/4090624-gsk-shingles-vaccine-shown-highly-effective-11-years-after-vaccination?source=feed_sector_healthcare
Apr 17, 2024 - GSK (GSK) said studies showed that its top-selling shingles vaccine, Shingrix, had an 82% efficacy rate 11 years after vaccination in people aged 50 and older. Read more here.
0
GSK plc (GSK) Q1 2024 Earnings Call Transcript
https://seekingalpha.com/article/4689355-gsk-plc-gsk-q1-2024-earnings-call-transcript?source=feed_sector_transcripts
May 03, 2024 - GSK plc (NYSE:NYSE:GSK) Q1 2024 Earnings Conference Call May 1, 2024 3:00 AM ETCompany ParticipantsNick Stone - Head of Investor RelationsEmma Walmsley -...
0
GSK faces another Zantac whistleblower lawsuit
https://seekingalpha.com/news/4108481-gsk-faces-another-zantac-whistleblower-lawsuit?source=feed_sector_healthcare
May 20, 2024 - A laboratory files a whistleblower lawsuit against GSK over the alleged presence of the cancer-causing chemical NDMA in heartburn drug Zantac. Read more here.
0
GSK wins first Zantac cancer jury trial (updated)
https://seekingalpha.com/news/4109935-gsk-wins-first-zantac-cancer-jury-trial?source=feed_sector_healthcare
May 23, 2024 - A Chicago jury dismisses a woman's claim that Zantac caused her colon cancer. Read more here.
0
Is Moderna Stock a Buy Now That It's a 2-Product Company?
https://www.fool.com/investing/2024/06/03/is-moderna-stock-a-buy-now-that-its-a-2-product-co/?source=iedfolrf0000001
Jun 03, 2024 - The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.
0
GSK says Blenrep combo cuts disease progression, death in multiple myeloma
https://seekingalpha.com/news/4112369-gsk-says-belnrep-combo-cuts-disease-progression-death-multiple-myeloma?source=feed_sector_healthcare
Jun 03, 2024 - GSK's Blenrep combination therapy reduces disease progression or death risk by nearly 50% compared to J&J's Velcade combo according to new data. Read more here.
0
GSK says new data buoys Jemperli as a treatment for rectal cancer
https://seekingalpha.com/news/4112388-gsk-says-new-data-buoys-jemperli-treatment-rectal-cancer?source=feed_sector_healthcare
Jun 03, 2024 - GSK's Jemperli (dostarlimab) is a potential alternative to surgery for rectal cancer patients, according to new phase 2 data. Read more here.
0
Page 1>